clinical trial · NCT07561554
Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
Haisco Pharmaceutical Group Co., Ltd.·phase1·recruiting·n = 159
Solid Tumors (Phase 1)HSK42360-Na
brief summary
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360-Na when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.
started
Mar 6, 2026
primary completion
Dec 2, 2028
completion
Dec 2, 2028
last updated
May 1, 2026
official title
A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of HSK42360-Na in Patients With BRAF V600 Mutation Locally Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol